Prevention of Atrial Fibrillation With Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers

This publication has 39 references indexed in Scilit:

• Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates 1
  Published by Elsevier ,2004
• Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials
  American Heart Journal, 2004
• Enalapril treatment and hospitalization with atrial tachyarrhythmias in patients with left ventricular dysfunction
  American Heart Journal, 2004
• Intra-Atrial Pressure Increases Rate and Organization of Waves Emanating From the Superior Pulmonary Veins During Atrial Fibrillation
  Circulation, 2003
• Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
  JAMA, 2002
• Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data
  Heart, 2001
• Meta-analysis. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996)
  Nephrology Dialysis Transplantation, 1998
• A Clinical Trial of the Angiotensin-Converting–Enzyme Inhibitor Trandolapril in Patients with Left Ventricular Dysfunction after Myocardial Infarction
  New England Journal of Medicine, 1995
• Effects of lisinopril in patients with heart failure and chronic atrial fibrillation
  Journal of Cardiac Failure, 1995
• Meta-analysis in clinical trials
  Controlled Clinical Trials, 1986